https://www.selleckchem.com/pr....oducts/aminoguanidin
32 (p less then 0.0001) when comparing high versus low FT3/FT4 ratio. In the placebo arm, median OS was 3.3, 5.6 and 7.7 months, in the three subgroups. HR for OS was 0.47 (p less then 0.0001) when comparing intermediate versus low and 0.33 (p less then 0.0001) when comparing high versus low. FT3/FT4 ratio retained its association with OS in the multivariate model in both arms. Conclusions While rejecting the predictive effect of baseline FT3/FT4 ratio, present data strengthen the prognostic role of the ratio, pave
Like
Comment
Share
